DRW Securities’s Aurinia Pharmaceuticals AUPH Stock Holding History

DRW Securities’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-27,009	Closed	-$229K	–	1287
2025 Q2	$229K	Buy	+27,009	New	+$217K	0.01%	889
2023 Q4	–	Sell	-25,050	Closed	-$195K	–	326
2023 Q3	$195K	Hold	25,050	–	–	﹤0.01%	314
2023 Q2	$242K	Sell	25,050 -18,902	-43%	-$196K	0.01%	283
2023 Q1	$482K	Buy	+43,952	New	+$387K	0.01%	207
2018 Q3	–	Sell	-31,300	Closed	-$176K	–	51
2018 Q2	$176K	Hold	31,300	–	–	0.01%	76
2018 Q1	$162K	Buy	+31,300	New	+$167K	0.01%	131

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DRW Securities's AUPH Position: Q3 2025 in Review

DRW Securities sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2025, closing a stake of 27,009 shares — an estimated $229K sold.

DRW Securities first reported a position in AUPH in Q1 2018 and held it in 6 quarters. The position peaked at $482K in Q1 2023. 242 funds tracked by Wall St. Rank hold AUPH as of Q3 2025.

DRW Securities reported no remaining Aurinia Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
DRW Securities sold 27,009 Aurinia Pharmaceuticals shares in Q3 2025, an estimated $229K.
DRW Securities first reported a position in Aurinia Pharmaceuticals in Q1 2018 and held it in 6 quarters.
DRW Securities's Aurinia Pharmaceuticals position peaked at $482K in Q1 2023.
242 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2025.

Based on DRW Securities's 13F filing for Q3 2025, filed 14 Nov 2025.